抗结核新药与新方案年度进展2024  

Annual progress of new drugs and new regimens for anti-tuberculosis treatment(2024)

作　　者：姚岚[1] 唐神结[2] Yao Lan;Tang Shenjie(Clinic and Research Centre of Tuberculosis,Shangnai Clinical Research Centre for Infectious Disease,Tongji University School of Medicine,Shanghai 200433,China;Beijing Chest Hospital,Capital Medical University,Beijing Tuberculosis and Thoracic Research Institute,Beijing 101149,China)

机构地区：[1]同济大学附属上海市肺科医院结核病临床研究中心,上海200433 [2]首都医科大学附属北京胸科医院,北京市结核病胸部肿瘤研究所结核病临床医学中心,北京101149

出　　处：《中华结核和呼吸杂志》2025年第2期170-175,共6页Chinese Journal of Tuberculosis and Respiratory Diseases

摘　　要：我国仍然是全球结核病高负担国家之一,估计每年发病患者为74.8万例,位列全球第三。面对“终止结核病策略”的要求,新药和新方案的研发是关键。目前已有多种新的抗结核药物处于临床试验阶段,如macozinone、sutezolid、alpibectir、GSK3036656等。已上市的药物如利奈唑胺、贝达喹啉、德拉马尼等药物的有效性、安全性和耐药问题也较受关注。同时,敏感和耐药结核病的短程治疗方案一直是临床研究的热点。世界卫生组织也更新了结核病高风险人群的预防性治疗的方案。本文就2023年10月1日至2024年9月30日发表的相关文献进行综述。China remains one of the countries with a high burden of tuberculosis(TB),with an estimated 748,000 cases each year,ranking third in the world.The research and development of new drugs and new protocols plays a key role in the face of the requirements of the WHO′s End TB Strategy.There are multiple new drugs in the clinical trial stage,such as macozinone,sutezoid,alpiberctin,and GSK3036656.The effectiveness,safety,and resistance issues of marketed drugs such as linezolid,bedaquiline,and delamanid are also of great concern.Meanwhile,short-term treatments for sensitive and drug-resistant TB have always been a hot topic in clinical research.WHO has also updated the preventive treatment plan for people at high risk of TB.This article reviews the literature published from October 1,2023 to September 30,2024.

关 键 词：预防性治疗 抗结核新药 高风险人群 利奈唑胺 耐药问题 耐药结核病 抗结核药物 GSK3 

分 类 号：R978.3[医药卫生—药品]